About Lan Li
Founded in August 2020, Lanli Bio is a one-stop biomedical integrated institution integrating preclinical efficacy evaluation, in vitro tumor pharmacology, DMPK, Non-GLP toxicology experiments, and pharmacological risk assessment. The team has a wealth of practical experience and successful case experience, will be able to effectively help customers scientifically and reasonably avoid risks. Lanli Bio has advanced scientific research capabilities and research models in the industry, and has advanced biomedical research and development capabilities and technologies, which can integrate technical resources in the industry.
Preclinical efficacy evaluation
-
in vitro tumor pharmacology
-
DMPK
-
Non-GLP Toxicology Experiment
-
One-stop medical service
-